A Phase 2 Study of Moderate Dose Interleukin-2 and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic or Unresectable Renal Cell Carcinoma
暂无分享,去创建一个
[1] M. Atkins,et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Atkins,et al. Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma , 2004, Clinical Cancer Research.
[3] M. Atkins,et al. Application of IL-2 and other cytokines in renal cancer , 2004, Expert opinion on biological therapy.
[4] S. Steinberg,et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Kersten,et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma , 2003, British Journal of Cancer.
[6] J. Fine,et al. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890) , 2003, Medical oncology.
[7] J. Glaspy. Therapeutic options in the management of renal cell carcinoma. , 2002, Seminars in oncology.
[8] T. Olencki,et al. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] G. Kramer,et al. Sequential Administration of Interferon-gamma, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II Trial. , 2001, Journal of immunotherapy.
[10] B. Dörken,et al. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon α in the treatment of metastatic renal cell carcinoma: a pilot study , 2001, Cancer Immunology, Immunotherapy.
[11] J. Sosman,et al. Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study , 2000 .
[12] M. Kersten,et al. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] C. Ryan,et al. Granulocyte‐macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma , 2000, Cancer.
[14] R. Fisher,et al. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. , 2000, The cancer journal from Scientific American.
[15] D. Dale,et al. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. , 1999, The Journal of infectious diseases.
[16] A. Ravaud,et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .
[17] B. Storer,et al. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] R. Fisher,et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Steinberg,et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Blay,et al. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. , 1994, British Journal of Cancer.
[21] N. Vogelzang,et al. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Richard,et al. Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies. , 1993, Bone marrow transplantation.
[23] D. Tweardy,et al. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction. , 1993, Blood.
[24] G. Masucci,et al. The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1a in combination with GM-CSF in the treatment of COLORECTAL CARCINOMA (CRC) , 1993, Medical Oncology and Tumor Pharmacotherapy.
[25] S. Rosenberg,et al. In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[26] D. Munn,et al. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor , 1990, The Journal of experimental medicine.
[27] A. Ho,et al. Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. , 1990, Blood.
[28] J. Gutterman,et al. Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. , 1988, Cancer research.